April 2021 // Investment

Synendos Series A Extension


Synendos Therapeutics is thrilled to announce an extension to the Series A financing with the addition of Ysios Capital to its syndicate of European investors. Ysios Capital’s contribution brings the total raised to CHF 24 million, following a Series A financing co-led by Kurma Partners and Sunstone Life Science Ventures announced in November 2020.


In addition, Synendos Therapeutics is delighted to announce securing a prestigious Eurostars grant (EU funding scheme) to expand proof-of-concept preclinical studies for PTSD and the appointment of Professor Jutta Heim as Chair to the Board.


Download here below the full press release.



Synendos Series A Extension 20April2021
Download • 166KB




Recent Posts

See All

October 2020 // Funding

Synendos and Prof. Jürg Gertsch received an Innosuisse Innovation Grant (total value of CHF 950’000).